Eur J Pediatr Surg 2012; 22(01): 029-033
DOI: 10.1055/s-0032-1306260
Original Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Elevated Serum IL-18 and Interferon-Gamma in Medium-Term Survivors of Biliary Atresia

P. Vejchapipat
1   Department of Surgery, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
,
S. Poomsawat
2   Department of Oral and Maxillofacial Pathology, Faculty of Dentistry, Mahidol University, Bangkok, Thailand
,
V. Chongsrisawat
3   Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
,
S. Honsawek
4   Department of Biochemistry, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
,
Y. Poovorawan
3   Department of Pediatrics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand
› Author Affiliations
Further Information

Publication History

14 May 2011

22 November 2011

Publication Date:
20 March 2012 (online)

Abstract

Introduction Biliary atresia (BA) is a fatal disease in children. Its main pathological feature is progressive immune-mediated cholangiopathy. Interleukin (IL)-12, IL-18, and interferon-gamma (IFN-gamma) play important roles in various immunological diseases. The objective was to investigate whether these serum markers were associated with clinical outcome in BA.

Methods Serum levels of IL-12, IL-18, and IFN-gamma were determined using enzyme-linked immunosorbent assay from 46 BA patients (median age of 9 years) and 19 normal controls. The BA patients were then categorized into three groups according to their outcome: jaundice-free (29 cases), mild to moderate jaundice (10 cases), and marked jaundice (7 cases). The comparisons of serum IL-12, IL-18, and IFN-gamma levels among groups of the patients were performed using one-way analysis of variance with post-hoc tests. Data are expressed as mean + standard deviation.

Results Serum IL-18 and IFN-gamma in BA patients were higher than the normal controls (IL-18: 113.3 + 82.6 vs. 80.5 + 9.9 pg/mL, p = 0.011 and IFN-gamma: 41.7 + 5.1 vs. 38.0 + 1.9 pg/mL, p < 0.001). There was no difference in serum IL-12 between BA and controls. Further analysis demonstrated that, in BA patients, only serum IL-18 levels significantly increased with the degree of jaundice (test for trend, p = 0.004).

Conclusions Serum IL-18 and IFN-gamma levels were increased in medium-term survivors of BA. The elevated serum IL-18 in BA patients was associated with worse clinical outcome. These results suggest that IL-18 and IFN-gamma play roles in the pathophysiology of BA. Additionally, IL-18 is likely to be involved in the disease progression.

 
  • References

  • 1 Kelly DA, Davenport M. Current management of biliary atresia. Arch Dis Child 2007; 92 (12) 1132-1135
  • 2 Nio M, Ohi R, Miyano T, Saeki M, Shiraki K, Tanaka K ; Japanese Biliary Atresia Registry. Five- and 10-year survival rates after surgery for biliary atresia: a report from the Japanese Biliary Atresia Registry. J Pediatr Surg 2003; 38 (7) 997-1000
  • 3 Ohi R. Surgery for biliary atresia. Liver 2001; 21 (3) 175-182
  • 4 Kobayashi H, Stringer MD. Biliary atresia. Semin Neonatol 2003; 8 (5) 383-391
  • 5 Utterson EC, Shepherd RW, Sokol RJ , et al; Split Research Group. Biliary atresia: clinical profiles, risk factors, and outcomes of 755 patients listed for liver transplantation. J Pediatr 2005; 147 (2) 180-185
  • 6 Narayanaswamy B, Gonde C, Tredger JM, Hussain M, Vergani D, Davenport M. Serial circulating markers of inflammation in biliary atresia—evolution of the post-operative inflammatory process. Hepatology 2007; 46 (1) 180-187
  • 7 Honsawek S, Chongsrisawat V, Vejchapipat P, Thawornsuk N, Tangkijvanich P, Poovorawan Y. Serum interleukin-8 in children with biliary atresia: relationship with disease stage and biochemical parameters. Pediatr Surg Int 2005; 21 (2) 73-77
  • 8 Kobayashi H, Yamataka A, Lane GJ, Miyano T. Levels of circulating antiinflammatory cytokine interleukin-1 receptor antagonist and proinflammatory cytokines at different stages of biliary atresia. J Pediatr Surg 2002; 37 (7) 1038-1041
  • 9 Vejchapipat P, Sookpotarom P, Theamboonlers A, Chittmittrapap S, Poovorawan Y. Elevated serum soluble E-selectin is associated with poor outcome and correlated with serum ALT in biliary atresia. Eur J Pediatr Surg 2008; 18 (4) 254-257
  • 10 Vejchapipat P, Theamboonlers A, Poomsawat S, Chittmittrapap S, Poovorawan Y. Serum transforming growth factor-beta1 and epidermal growth factor in biliary atresia. Eur J Pediatr Surg 2008; 18 (6) 415-418
  • 11 Vejchapipat P, Theamboonlers A, Chaokhonchai R, Chongsrisawat V, Chittmittrapap S, Poovorawan Y. Serum hepatocyte growth factor and clinical outcome in biliary atresia. J Pediatr Surg 2004; 39 (7) 1045-1049
  • 12 Vejchapipat P, Poomsawat S, Imvised T, Chongsrisawat V, Chittmittrapap S, Poovorawan Y. Overexpression of hepatic inducible nitric oxide synthase in biliary atresia. Hepatol Res 2008; 38 (10) 1018-1025
  • 13 Vejchapipat P, Chongsrisawat V, Theamboonlers A, Chittmittrapap S, Poovorawan Y. Elevated serum nitric oxide metabolites in biliary atresia. Pediatr Surg Int 2006; 22 (1) 106-109
  • 14 Sasaki H, Nio M, Iwami D , et al. E-cadherin, alpha-catenin and beta-catenin in biliary atresia: correlation with apoptosis and cell cycle. Pathol Int 2001; 51 (12) 923-932
  • 15 Funaki N, Sasano H, Shizawa S , et al. Apoptosis and cell proliferation in biliary atresia. J Pathol 1998; 186 (4) 429-433
  • 16 Erickson N, Mohanty SK, Shivakumar P, Sabla G, Chakraborty R, Bezerra JA. Temporal-spatial activation of apoptosis and epithelial injury in murine experimental biliary atresia. Hepatology 2008; 47 (5) 1567-1577
  • 17 Vejchapipat P, Jirapanakorn N, Thawornsuk N , et al. There is no association between K469E ICAM-1 gene polymorphism and biliary atresia. World J Gastroenterol 2005; 11 (31) 4886-4890
  • 18 Sakaida I, Uchida K, Matsumura Y, Okita K. Interferon gamma treatment prevents procollagen gene expression without affecting transforming growth factor-beta1 expression in pig serum-induced rat liver fibrosis in vivo. J Hepatol 1998; 28 (3) 471-479
  • 19 Chikano S, Sawada K, Shimoyama T , et al. IL-18 and IL-12 induce intestinal inflammation and fatty liver in mice in an IFN-gamma dependent manner. Gut 2000; 47 (6) 779-786
  • 20 Otani T, Nakamura S, Toki M, Motoda R, Kurimoto M, Orita K. Identification of IFN-gamma-producing cells in IL-12/IL-18-treated mice. Cell Immunol 1999; 198 (2) 111-119
  • 21 Kawakami K, Koguchi Y, Qureshi MH , et al. IL-18 contributes to host resistance against infection with Cryptococcus neoformans in mice with defective IL-12 synthesis through induction of IFN-gamma production by NK cells. J Immunol 2000; 165 (2) 941-947
  • 22 Bezerra JA. Biliary atresia—translational research on key molecular processes regulating biliary injury and obstruction. Chang Gung Med J 2006; 29 (3) 222-230
  • 23 Mohanty SK, Shivakumar P, Sabla G, Bezerra JA. Loss of interleukin-12 modifies the pro-inflammatory response but does not prevent duct obstruction in experimental biliary atresia. BMC Gastroenterol 2006; 6: 14
  • 24 Micallef MJ, Ohtsuki T, Kohno K , et al. Interferon-gamma-inducing factor enhances T helper 1 cytokine production by stimulated human T cells: synergism with interleukin-12 for interferon-gamma production. Eur J Immunol 1996; 26 (7) 1647-1651
  • 25 Mack CL, Tucker RM, Sokol RJ , et al. Biliary atresia is associated with CD4+ Th1 cell-mediated portal tract inflammation. Pediatr Res 2004; 56 (1) 79-87
  • 26 Yamano T, Higashi T, Nouso K , et al. Serum interferon-gamma-inducing factor/IL-18 levels in primary biliary cirrhosis. Clin Exp Immunol 2000; 122 (2) 227-231
  • 27 Sharma A, Chakraborti A, Das A, Dhiman RK, Chawla Y. Elevation of interleukin-18 in chronic hepatitis C: implications for hepatitis C virus pathogenesis. Immunology 2009; 128 (1, Suppl) e514-e522
  • 28 Urushihara N, Iwagaki H, Yagi T , et al. Elevation of serum interleukin-18 levels and activation of Kupffer cells in biliary atresia. J Pediatr Surg 2000; 35 (3) 446-449